Conditions: Postmenopausal Women With Osteoporosis
Keywords: Postmenopausal Women Osteoporosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 61
Healthy volunteers: no

Brief summary:
The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.

Detailed description:

Arms:
arm 1: Placebo years 1-5, Risedronate 5mg/day years 6 \& 7, no drug year 8 arm 2: Risedronate 5mg years 1-7, no drug year 8

Interventions: intervention 1: Risedronate intervention 2: Placebo/Risedronate
Intervention descriptions: intervention 1: 5 mg/day intervention 2: placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8

Protocol document: